The role of cerebral amyloid β accumulation in common forms of Alzheimer disease

Research output: Contribution to journalReview articlepeer-review

398 Scopus citations

Abstract

For approximately 80 years following Alzheimer's description of the disease that bears his name, a gulf divided researchers who believed that extracellular deposits of the amyloid β (Aβ) peptide were pathogenic from those who believed that the deposits were secondary detritus. Since 1990, the discoveries of missense mutations in the Aβ peptide precursor (APP) and the APP-cleaving enzyme presenilin 1 (PS1) have enabled much progress in understanding the molecular, cellular, and tissue pathology of the aggregates that accumulate in the interstices of the brains of patients with autosomal dominant familial Alzheimer disease (AD). Clarification of the molecular basis of common forms of AD has been more elusive. The central questions in common AD focus on whether cerebral and cerebrovascular Aβ accumulation is (a) a final neurotoxic pathway, common to all forms of AD; (b) a toxic by-product of an independent primary metabolic lesion that, by itself, is also neurotoxic; or (c) an inert by-product of an independent primary neurotoxic reaction. Antiamyloid medications are entering clinical trials so that researchers can evaluate whether abolition of cerebral amyloidosis can mitigate, treat, or prevent the dementia associated with common forms of AD. Successful development of antiamyloid medications is critical for elucidating the role of Aβ in common AD.

Original languageEnglish
Pages (from-to)1121-1129
Number of pages9
JournalJournal of Clinical Investigation
Volume115
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'The role of cerebral amyloid β accumulation in common forms of Alzheimer disease'. Together they form a unique fingerprint.

Cite this